Practical Treatment Questions Surface in HR-Positive Metastatic Breast Cancer

Christin Melton, ELS
Published: Thursday, Mar 07, 2019
Joyce A. O’Shaughnessy, MD

Joyce A. O’Shaughnessy, MD

Novel and emerging agents are creating exciting new options for patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), resulting in the need to consider how best to introduce and sequence these agents into the treatment timeline, experts say.

Incorporating CDK4/6 Inhibitors

The FDA has approved 3 oral CDK4/6 inhibitors for HR-positive, HER2-negative MBC: palbociclib (Ibrance),4 ribociclib (Kisqali),5 and abemaciclib (Verzenio).6 Although the CDK4/6 inhibitors have slightly different indications, all are typically administered with an aromatase inhibitor (AI) in the first-line setting or with fulvestrant (Faslodex), an injectable selective ER modulator, in the second-line setting. Ribociclib is the only CDK4/6 inhibitor indicated for first-line therapy in pre- or perimenopausal women in addition to postmenopausal women.5
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x